Phase 2Completed

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma

Sponsor
Corixa Corporation (Industry)
Conditions
Mantle Cell Lymphoma
Interventions
Iodine-131 Anti-B1 Antibody; Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
Ages
adults, older adults
Registry
NCT00022945

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody followed by CHOP and to see what effects it has on patients with previously untreated mantel cell lymphoma.

History

  1. Last registry update

  2. Registered